Novartis
NEWS
Teva and Mylan are looking over their shoulders this morning after the FDA gave Novartis and Momenta the green light for their Copaxone copycat drug.
Today STADA announced the appointment of Peter Goldschmidt as new CEO and chairman of the board.
BridgeBio stepped in to take over the drug and also launch a subsidiary, QED Therapeutics, to drive the development of infigratinib.
Sanofi has announced major restructuring, which will involve about 400 job cuts in the U.S.
During an international conference in Davos, Switzerland, President Donald Trump sat down with the leaders of several European life science companies to encourage more investment in the United States.
Joseph Jimenez retires at the end of the month after eight years in the top job at Novartis.
Entresto, introduced in 2015, got off to a slow start but brought in $507 million in revenue last year.
Narasimhan takes over the role of CEO in February as current CEO Joe Jimenez retires.
Life sciences professionals don’t have to look far for opportunity in Genetown.
JOBS
IN THE PRESS